Direct Answer
Boston Scientific reports revenue across 2 business segments in its fiscal 2025 Form 10-K. Cardiovascular is the largest, with $13.3 billion of revenue (66% of the total), followed by Medsurg at $6.8 billion (34%). 64% of revenue came from the United States.
How Does Boston Scientific Make Money?
Cardiovascular supplies 66% of revenue, so Boston Scientific's results move mostly with that one business; the others matter more for diversification than for the headline number. Between fiscal 2024 and 2025, Cardiovascular grew fastest (+23.2%) and Medsurg slowest (+13.9%), so the revenue mix tilts toward Cardiovascular while that gap lasts.
| Segment | FY2025 revenue | FY2024 revenue | Share of revenue | Change |
|---|---|---|---|---|
| Cardiovascular | $13.3 billion | $10.8 billion | 66.0% | 23.2% |
| Medsurg | $6.8 billion | $6.0 billion | 34.0% | 13.9% |
Where Does Boston Scientific's Revenue Come From?
Regions follow the definitions in the filing; most companies assign revenue by customer location.
| Region | FY2025 revenue | FY2024 revenue | Share of revenue | Change |
|---|---|---|---|---|
| United States | $12.9 billion | $10.2 billion | 64.1% | 26.0% |
| EMEA | $3.5 billion | $3.2 billion | 17.2% | 6.9% |
| Asia Pacific | $3.1 billion | $2.7 billion | 15.3% | 14.7% |
| Emerging Markets | $3.0 billion | $2.7 billion | 14.9% | 11.4% |
| Latin America and Canada | $678 million | $624 million | 3.4% | 8.7% |
What the Segment Figures Do Not Show
The rows above add up to 100% of Boston Scientific's reported revenue for fiscal 2025; the difference is intersegment eliminations, corporate revenue or items the company reports outside its segments. Segment definitions are management's choice and change when a company reorganizes, in which case it restates prior years in the next filing, so a multi-year comparison should use the figures from a single filing. Revenue shows where sales come from, not where profit or cash is earned: a small segment can carry most of the margin.
Where These Numbers Come From
Every figure on this page is a value Boston Scientific reported in the segment note and revenue disclosures of its Form 10-K filed February 17, 2026 (accession 0000885725-26-000010), read from the SEC's Financial Statement Data Sets. The prior-year column is the comparative figure from that same filing, so it reflects any restatement for a change in segments. Category names are the company's own XBRL labels, lightly reformatted for reading.
Rows that only total other rows (for example a "Products" line beside the individual products) are left out so nothing is counted twice. This page is educational and describes reported history for fiscal 2025; it is not a forecast or a recommendation.
Frequently Asked Questions
What are Boston Scientific's business segments?
In its fiscal 2025 Form 10-K, Boston Scientific reports revenue for Cardiovascular and Medsurg.
Which part of Boston Scientific brings in the most revenue?
Cardiovascular, with $13.3 billion of revenue in fiscal 2025, or 66% of the total.
How much of Boston Scientific's revenue comes from outside the United States?
36% in fiscal 2025, by the geographic breakdown Boston Scientific reports in its Form 10-K. Companies assign revenue to regions differently (customer location, shipping address or selling entity), so check the filing's definition before comparing companies.